WARF: P100078US02

Improved Production of Influenza Virus, Including H1N1, for Vaccine Manufacture


Yoshihiro Kawaoka, Taisuke Horimoto, Shin Murakami

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method and composition for improving production of vaccines against influenza viruses, including H1N1.
OVERVIEWThe H1N1 influenza virus, known as the “swine flu,” has been declared a pandemic.  While this virus is less virulent than many circulating strains of flu virus, it has become the subject of significant public health efforts, including international stockpiling of vaccine.  However, this virus is less amenable to high titer production than many of the more common influenza viruses, making vaccine manufacture challenging.
THE INVENTIONUW-Madison researchers have identified a single point mutation in the haemagglutinin (HA) gene of the H1N1 virus that enhances viral titer.  Introducing the mutation into vaccine seed viruses could lead to higher titer production of the viruses, improving vaccine manufacture.
  • Production of H1N1 vaccine
  • Production of vaccines against other viruses
  • Viral mutagenesis studies
  • Identification of other HA mutations that alter growth of influenza virus
  • Significantly improves growth of influenza virus in cultured cells, including Vero cells
  • Enhances manufacturing of influenza vaccines, including vaccines against the H1N1 strain
  • Does not require helper virus
STAGE OF DEVELOPMENTThis mutation enhanced replication of H1N1 more than 1000 times in a cell line approved for human vaccine production.
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.